ABSTRACT: 2 0
Asthma is a common, under-diagnosed disease affecting all ages. We sought to identify a nasal 2 1 brush-based classifier of mild/moderate asthma. 190 subjects with mild/moderate asthma and 2 2 controls underwent nasal brushing and RNA sequencing of nasal samples. A machine learning-2 3 based pipeline identified an asthma classifier consisting of 90 genes interpreted via an L2-2 4
regularized logistic regression classification model. This classifier performed with strong 2 5 predictive value and sensitivity across eight test sets, including (1) a test set of independent 2 6 asthmatic and control subjects profiled by RNA sequencing (positive and negative predictive 2 7 values of 1.00 and 0.96, respectively; AUC of 0.994), (2) two independent case-control cohorts 2 8 of asthma profiled by microarray, and (3) five cohorts with other respiratory conditions (allergic 2 9 rhinitis, upper respiratory infection, cystic fibrosis, smoking), where the classifier had a low to 3 0 zero misclassification rate. Following validation in large, prospective cohorts, this classifier could 3 1 be developed into a nasal biomarker of asthma. 3 2 Introduction 3 3
Asthma is a chronic respiratory disease that affects 8.6% of children and 7.4% of adults 3 4 in the United States [1] . Its true prevalence may be higher [2] . The fluctuating airflow 3 5 obstruction, bronchial hyper-responsiveness, and airway inflammation that characterize mild to 3 6 moderate asthma can be difficult to detect in busy, routine clinical settings [3] . In one study of 3 7 US middle school children, 11% reported physician-diagnosed asthma with current symptoms, 3 8
while an additional 17% reported active asthma-like symptoms without a diagnosis of asthma 3 9 [2] . Undiagnosed asthma leads to missed school and work, restricted activity, emergency 4 0 department visits, and hospitalizations [2, 4] . Given the high prevalence of asthma and 4 1 consequences of missed diagnosis, there is high potential impact of improved biomarkers for 4 2 asthma [5] . 4 3 National and international guidelines recommend that the diagnosis of asthma be based 4 4 on a history of typical symptoms and objective findings of variable expiratory airflow limitation [6, 4 5 7]. However, obtaining such objective findings can be challenging given currently available 4 6 tools. Pulmonary function tests (PFTs) require equipment, expertise, and experience to execute 4 7 well [8, 9] . Results are unreliable if the procedure is done with poor technique [8] . PFTs are 4 8 usually not immediately available in primary care settings. Despite the published guidelines, 4 9
PFTs are not done in over half of patients suspected of having asthma [8] . Induced sputum and 5 0 exhaled nitric oxide have been explored as asthma biomarkers, but their implementation 5 1 requires technical expertise and does not yield better clinical results than physician-guided 5 2 management alone [10] . Given the above, the reality is that most asthma is still clinically 5 3 diagnosed and managed based on self-report [8, 9] . This is problematic because most patients 5 4 with asthma are frequently asymptomatic at the time of exam and under-perceive as well as 5 5
under-report symptoms [11] .
6
A nasal biomarker of asthma is of high interest given the accessibility of the nose and 5 7 shared airway biology between the upper and lower respiratory tracts [12] [13] [14] [15] . The easily 5 8 P a n d e y e t a l . , p . 4 accessible nasal passages are directly connected to the lungs and exposed to common 5 9
Results

7
Study population and baseline characteristics 7 8
We performed nasal brushing on 190 subjects for this study, including 66 subjects with 7 9 well-defined mild to moderate persistent asthma (based on symptoms, medication need, and 8 0 demonstrated airway hyper-responsiveness by methacholine challenge) and 124 subjects 8 1 without asthma (based on no personal or family history of asthma, normal spirometry, and no 8 2 bronchodilator response). The definitional criteria we used for mild-moderate asthma are 8 3 consistent with US National Heart Lung Blood Institute guidelines for the diagnosis of asthma 8 4 P a n d e y e t a l . , p . 5
[7], and are the same criteria used in the longest NIH-sponsored study of mild-moderate asthma 8 5 RNA isolated from nasal brushings from the subjects was of good quality, with mean RIN 1 0 1 7.8 (±1.1). The median number of paired-end reads per sample from RNA sequencing was 36.3 1 0 2 million. Following pre-processing (normalization and filtering) of the raw RNAseq data, 11,587 1 0 3 genes were used for statistical and machine learning analysis. variancePartition analysis [22] , 1 0 4 which is designed to analyze the contribution of technical and biological factors to variation in 1 0 5 gene expression, showed that age, race, and sex contributed minimally to total gene expression 1 0 6 variance (Supplementary Figure 1) . For this reason, we did not adjust the pre-processed 1 0 7
RNAseq data for these factors. 1 0 8 Differential gene expression analysis by DeSeq2 [23] showed that 1613 and 1259 genes 1 0 9
were respectively over-and under-expressed in asthma cases versus controls (false discovery 1 1 0 P a n d e y e t a l . , p . 6 rate (FDR) ≤ 0.05) ( Supplementary Table 1 ). These genes were enriched for disease-relevant 1 1 1 pathways in the Molecular Signature Database [24], including immune system (fold change=3.6, 1 1 2 FDR=1.07 x 10 -22 ), adaptive immune system (fold change=3.91, FDR=1.46 x 10 -15 ), and innate 1 1 3 immune system (fold change=4.1, FDR=4.47 x 10 -9 ) ( Supplementary Table 1 ). 1 1 4 1 1 5
Identifying a nasal brush-based asthma classifier 1 1 6
To identify a nasal brush-based asthma classifier using the RNAseq data generated, we 1 1 7 developed a machine learning pipeline that combined feature (gene) selection [16] and 1 1 8 classification techniques [17] that was applied to the development set (Materials and Methods 1 1 9
and Supplementary Figure 2) . This pipeline was designed with a systems biology-based 1 2 0 perspective that a set of genes, even ones with marginal effects, can collectively classify 1 2 1 phenotypes (here asthma) more accurately than individual genes [25] . More specifically, the 1 2 2 goal of building such a classifier is not to elucidate the cause or molecular biology of the 1 2 3 disease, but rather to identify features (genes in our study) that in combination can discriminate 1 2 4 between groups of interest (e.g. asthma and no asthma). Such a classifier is likely to include 1 2 5 genes known to associate with the groups, but it is also possible and even likely (given our 1 2 6 incomplete understanding of complex diseases such as asthma) that genes not previously 1 2 7 associated with the groups can provide information that is useful to the discrimination. This type 1 2 8 of data-driven approach has been successful in other disease areas, especially cancer [26-29]. 1 2 9
Feature selection [16] is the process of identifying a subset of features (e.g. genes) from 1 3 0 a much larger subset in an automated data-driven fashion. In our pipeline, this process involved 1 3 1 a cross validation-based protocol [30] Figure 3) . Classification analysis was then 1 3 5 Forest, and Logistic) [17] to the expression profiles of the gene sets identified by feature 1 3 7 selection. To reduce the potential adverse effect of overfitting, this process (feature selection 1 3 8 and classification) was repeated 100 times on 100 random splits of the development set into 1 3 9
training and holdout sets. The final classifier was selected by statistically comparing the models 1 4 0 in terms of both classification performance and parsimony, i.e., the number of genes included in 1 4 1 the model [18] (Supplementary Figure 4) . 1 4 2
Due to the imbalance of the two classes (asthma and controls) in our cohort (consistent 1 4 3 with imbalances in the general population for asthma and most disease states), we used F-1 4 4 measure as the main evaluation metric in our study [31, 32] . This class-specific measure is a 1 4 5 conservative mean of precision (predictive value) and recall (same as sensitivity), and is 1 4 6 described in detail in Box 1 and Supplementary Figure 5 . F-measure can range from 0 to 1, 1 4 7
with higher values indicating superior classification performance. An F-measure value of 0.5 1 4 8 does not represent a random model. To provide context for our performance assessments, we 1 4 9 also computed commonly used evaluation measures, including positive and negative predictive 1 5 0 values (PPVs and NPVs) and Area Under the Receiver Operating Characteristic (ROC) Curve 1 5 1 (AUC) scores (Box 1 and Supplementary Figure 5 ). 1 5 2 P a n d e y e t a l . , p P a n d e y e t a l . , p . 9
The best performing and most parsimonious combination of feature selection and 1 7 7 classification algorithm identified by our machine learning pipeline was LR-RFE & Logistic 1 7 8
Regression (Supplementary Figure 4) . The classifier inferred using this combination was built 1 7 9 on 90 predictive genes and will be henceforth referred to as the asthma classifier. We 1 8 0 emphasize that the expression values of the classifier's 90 genes must be used in combination 1 8 1 with the Logistic classifier and the model's optimal classification threshold (i.e. predicted 1 8 2 label=asthma if classifier's probability output≥0.76, else predicted label=no asthma) to be used 1 8 3 effectively for asthma classification. 1 8 4 known disease-related genes, allowing for the identification of a parsimonious set of genes that 3 0 0 collectively enabled accurate disease classification. 3 0 1 P a n d e y e t a l . , p . 1 4 Discussion 3 0 2
Using RNAseq data generated from our cohorts, combined with a systematic machine 3 0 3 learning analysis approach, we identified a nasal brush-based classifier that accurately 3 0 4 distinguishes subjects with mild/moderate asthma from controls. This asthma classifier, 3 0 5 consisting of the expression profiles of 90 genes interpreted via a logistic regression 3 0 6 classification model, performed with high precision (PPV=1.00 and NPV=0.96) and recall for 3 0 7 classifying asthma (AUC=0.994). The performance of the asthma classifier across independent 3 0 8 test sets demonstrates potential for the classifier's generalizability across study populations and 3 0 9 two major modalities of gene expression profiling (RNAseq and microarray). Additionally, the 3 1 0 classifier's low to zero rate of misclassification on external cohorts with non-asthma respiratory 3 1 1 conditions supports the specificity of this asthma classifier. Our results represent the first steps 3 1 2 toward the development of a nasal biomarker of asthma. 3 1 3
Our nasal brush-based asthma classifier is based on the common biology of the upper 3 1 4 and lower airway, a concept supported by clinical practice and previous findings [12] [13] [14] [15] . 3 1 5
Clinicians often rely on the united airway by screening for lower airway infections (e.g. influenza, 3 1 6 methicillin-resistant Staphylococcus aureus) with nasal swabs [42] . Sridhar et al. found that 3 1 7 gene expression consequences of tobacco smoking in bronchial epithelial cells were reflected in 3 1 8 nasal epithelium [12] . Wagener et al. compared gene expression in the nasal and bronchial 3 1 9 epithelia from 17 subjects, finding that 99% of the 33,000 genes tested exhibited no differential 3 2 0 expression between the nasal and bronchial epithelia in those with airway disease [13] . In a 3 2 1 study of 30 children, Guajardo et al. identified gene clusters with differential expression in nasal 3 2 2 epithelium between subjects with exacerbated asthma vs. controls [14] . The above studies were 3 2 3 done with small sample sizes and microarray technology. More recently, Poole et al. compared 3 2 4
RNAseq profiles of nasal brushings from 10 asthmatic and 10 control subjects to publicly 3 2 5 available bronchial transcriptional data, finding correlation (ρ = 0.87) between nasal and 3 2 6 bronchial transcripts, as well as correlation (ρ=0.77) between nasal differential expression and 3 2 7 P a n d e y e t a l . , p . 1 5 previously observed bronchial differential expression in asthmatics [15] . To the best of our 3 2 8 knowledge, our study has generated the largest nasal RNAseq data set in asthma to date and is 3 2 9 the first to identify a nasal brush-based classifier of asthma. 3 3 0 Although based on only 90 genes, our asthma classifier classified asthma with greater 3 3 1 accuracy than models based on all genes, all differentially expressed genes, and known asthma 3 3 2 genes (Figure 4) . Its superior performance supports that our machine learning pipeline 3 3 3 successfully selected a parsimonious set of informative genes that (1) captures more actionable 3 3 4 knowledge than traditional differential expression and genetic association analyses, and (2) cuts 3 3 5 through the potential noise of genes irrelevant to asthma. These results illustrate that data-3 3 6 driven methods can build more effective classifiers than those built exclusively on current 3 3 7 domain knowledge. This is likely true not just for asthma but for other phenotypes as well. About 3 3 8 half the genes in our asthma classifier were not differentially expressed at FDR ≤ 0.05, and as 3 3 9 such would not have been examined with greater interest had we only performed traditional 3 4 0 differential expression analysis, which is the main analytic approach of virtually all studies of 3 4 1 gene expression in asthma [12-15, 43, 44] . Consistent with motivations underlying systems 3 4 2 biology and genomic approaches [25, 45] , our study demonstrated that the asthma classifier 3 4 3 captures signal from differential expression as well as genes below traditional significance 3 4 4 thresholds that may still have a contributory role to asthma classification. 3 4 5
With prospective validation in large cohorts, our asthma classifier could lead to the 3 4 6 development of a minimally invasive biomarker to aid asthma diagnosis at clinical frontlines, 3 4 7
where time and resources often preclude pulmonary function testing (PFT). Nasal brushing can 3 4 8 be performed quickly, does not require machinery for collection, and implementation of our 3 4 9 classification model yields a straightforward, binary result of asthma or no asthma. Because it 3 5 0 takes seconds for nasal brushing and bioinformatic interpretation could be automated, an 3 5 1 asthma classifier such as ours may be attractive to time-strapped clinicians, particularly primary 3 5 2 care providers at the frontlines of asthma diagnosis. Asthma is frequently diagnosed and treated 3 5 3 P a n d e y e t a l . , p Table 3 ). Subjects from the Asthma2 cohort were adults who were classified as having asthma 3 6 8 or healthy based on history. As mentioned, the diagnosis of asthma based on history alone 3 6 9 without objective lung function testing can be inaccurate [49] . The phenotypic differences 3 7 0 between these test sets alone could explain differences in performance of our asthma classifier 3 7 1 in these test sets. Second, the differential performance may be due to the difference in profiling 3 7 2 approach. Gene mappings do not perfectly correspond between RNAseq and microarray due to 3 7 3 disparities between array annotations and RNAseq gene models [38] . Compared to 3 7 4 microarrays, RNAseq quantifies more RNA species and captures a wider range of signal [43]. 3 7 5
Prior studies have shown that microarray-derived models can reliably predict phenotypes based 3 7 6 on samples' RNAseq profiles, but the converse does not often hold [38] . Despite the above 3 7 7 limitations, our asthma classifier performed with reasonable accuracy in classifying asthma in 3 7 8 these independent microarray-based test sets. These results support a degree of 3 7 9 P a n d e y e t a l . , p . 1 7 generalizability of our classifier to asthma populations that may be phenotyped or profiled 3 8 0 differently.
8 1
An effective clinical classifier should have good positive and negative predictive value 3 8 2 [50] . This was indeed the case with our asthma classifier, which achieved high positive and 3 8 3
negative predictive values of 1.00 and 0.96 respectively in the RNAseq test set. We also tested 3 8 4 our asthma classifier on independent tests sets of subjects with allergic rhinitis, upper 3 8 5 respiratory infection, cystic fibrosis, and smoking, and showed that the classifier had a low to 3 8 6 zero rate of misclassifying other respiratory conditions as asthma ( Figure 5) . These results 3 8 7 were particularly notable for allergic rhinitis, a predominantly nasal condition. Although our 3 8 8 classifier is based on nasal gene expression, and asthma and allergic rhinitis frequently co-3 8 9 occur [21], our classifier did not misclassify allergic rhinitis as asthma. Although these 3 9 0 conclusions are based on relatively small test sets due to the scarcity of nasal gene expression 3 9 1 data in the public domain, the performance of our classifier gives hope that it has the potential to 3 9 2 be generalizable and specific in much larger cohorts as well. 3 9 3
Although we have generated one of the largest nasal RNAseq data set in asthma to 3 9 4 date, a future direction of this study is to recruit additional cohorts for nasal gene expression 3 9 5 profiling and extend validation of our findings in a prospective manner. We recognize that our 3 9 6 development set was from a single center and its baseline characteristics, such as race, do not 3 9 7 characterize all populations. However, we find it reassuring that the classifier performed 3 9 8 reasonably well in multiple external data sets spanning children and adults of varied racial 3 9 9 distributions, and with asthma and other respiratory conditions defined by heterogeneous 4 0 0 criteria. Subjects with asthma in our development cohort were not all symptomatic at the time of 4 0 1 sampling. The fact that the performance of our asthma classifier does not rely on symptomatic 4 0 2 asthma is a strength, as many mild/moderate asthmatics are only sporadically symptomatic 4 0 3
given the fluctuating nature of the disease. 4 0 4 P a n d e y e t a l . , p . 1 8
We see our nasal brush-based classifier of asthma as the first step in the development 4 0 5 of nasal biomarkers for asthma care. As with any disease, the first step is to accurately identify 4 0 6 affected patients. The asthma gene panel described in this study provides an accurate initial 4 0 7 path to this critical diagnostic step. With a correct diagnosis, an array of existing asthma 4 0 8 treatment options can be considered [6] . A next phase of research will be to develop a nasal 4 0 9 biomarker to predict endotypes and treatment response, so that asthma treatment can be 4 1 0 targeted, and even personalized, with greater efficiency and effectiveness [51] . 4 1 1
In summary, we demonstrated an innovative application of RNA sequencing and 4 1 2 machine learning to identify a classifier consisting of genes expressed in nasal brushings that 4 1 3 accurately classifies subjects with mild/moderate asthma from controls. This asthma classifier 4 1 4 performed with accuracy across independent and external test sets, indicating reasonable 4 1 5 generalizability across study populations and gene expression profiling modality, as well as 4 1 6 specificity to asthma. This asthma classifier could potentially lead to the development of a nasal 4 1 7 biomarker of asthma. 4 1 8 P a n d e y e t a l . , p . 1 9
Materials and Methods 4 1 9
Study design and subjects 4 2 0 Subjects with mild/moderate asthma were a subset of participants of the Childhood 4 2 1 Asthma Management Program (CAMP), a multicenter North American study of 1041 subjects 4 2 2 with mild to moderate persistent asthma [19, 20] . Findings from the CAMP cohort have defined 4 2 3 current practice and guidelines for asthma care and research [20] . Asthma was defined by 4 2 4 symptoms ≥ 2 times per week, use of an inhaled bronchodilator ≥ twice weekly or use of daily 4 2 5 medication for asthma, and increased airway responsiveness to methacholine (PC 20 ≤ 12.5 4 2 6 mg/ml). The subset of subjects included in this study were CAMP participants who presented for 4 2 7 a visit between July 2011 and June 2012 at Brigham and Women's Hospital (Boston, MA), one 4 2 8 of the eight study centers for CAMP. 4 2 9
Subjects with "no asthma" were recruited during the same time period by advertisement 4 3 0 at Brigham & Women's Hospital. Selection criteria were no personal history of asthma, no family 4 3 1 history of asthma in first-degree relatives, and self-described Caucasian ethnicity. Participation 4 3 2 was limited to Caucasian individuals because a concurrent independent study was planned that 4 3 3 would compare these same subjects to 968 Caucasian CAMP subjects who participated in the 4 3 4
CAMP Genetics Ancillary study [52] . Subjects underwent pre-and post-bronchodilator 4 3 5 were subjected to quality control with FastQC and RNA-SeQC [57] . Data were pre-processed 4 5 7 separately for the development and test sets to avoid leakage of information across the two data 4 5 8 sets and maintain fairness of the machine learning procedures as much as possible. Genes with 4 5 9 fewer than 100 counts in at least half the samples were dropped to reduce the potentially 4 6 0 adverse effects of noise. DESeq2 [23] was used to normalize the data sets using its variance 4 6 1 stabilizing transformation method. 4 6 2 4 6 3
VariancePartition Analysis of Potential Confounders 4 6 4
Given differences in age, race, and sex distributions between the asthma and "no 4 6 5 asthma" classes, we used the variancePartition method [22] to assess the degree to which 4 6 6 these variables influenced gene expression and potentially confounded the target phenotype 4 6 7 (asthma status). The total variance in gene expression was partitioned into the variance 4 6 8 attributable to age, race, and sex using a linear mixed model implemented in variancePartition 4 6 9 P a n d e y e t a l . , p . 2 1 v1.0.0 [22] . Age (continuous variable) was modeled as a fixed effect, while race and sex 4 7 0 (categorical variables) were modeled as random effects. The results showed that age, race, and 4 7 1 sex accounted for minimal contributions to total gene expression variance (Supplementary 4 7 2 To identify gene expression-based classifiers that predict asthma status, we applied a 4 8 5 rigorous machine learning pipeline that combined feature (gene) selection [16] , classification 4 8 6 [17] , and statistical analyses of classification performance [18] to the development set 4 8 7 (Supplementary Figure 2) . The pipeline was implemented in Python using the scikit-learn 4 8 8 package [58] . Feature selection and classification were applied to a training set comprised of 4 8 9 120 randomly selected samples from the development set (n=150) as described below. For an 4 9 0 independent evaluation of the candidate classifiers generated from the training set by this 4 9 1 process, they were then evaluated on the remaining 30 samples (holdout set). Finally, to reduce 4 9 2 the dependence of the finally chosen classifier on a specific training-holdout split, this process 4 9 3 was repeated 100 times on 100 random splits of the development set into training and holdout 4 9 4 sets. The details of the overall process as well as the individual components are as follows. 4 9 5 P a n d e y e t a l . , p .
2 2
Feature selection: The purpose of the feature selection component was to identify 4 9 6 subsets of the full set of genes in the development set, whose expression profiles could be used 4 9 7
to predict the asthma status as accurately as possible. The two main computations constituting 4 9 8 this component were (i) the optimal number of features that should be selected, and (ii) the 4 9 9 identification of this number of genes from the full gene set. To reduce the likelihood of 5 0 0 overfitting when conducting both these computations on the entire training set, we used a 5x5 5 0 1 nested (outer and inner) cross-validation (CV) setup [30] for selecting features from the training 5 0 2 set (Supplementary Figure 3) . The inner CV round was used to determine the optimal number 5 0 3 of genes to be selected, and the outer CV round was used to select the set of predictive genes 5 0 4 based on this number, thus separating the samples on which these decisions are made. The 5 0 5
supervised Recursive Feature Elimination (RFE) algorithm [59] was executed on the inner CV 5 0 6 training split to determine the optimal number of features. The use of RFE within this setting 5 0 7 enabled us to identify groups of features that are collectively, but not necessarily individually, 5 0 8
predictive. Specifically, we used the L2-regularized Logistic Regression (LR or Logistic) [60] and 5 0 9 SVM-Linear (kernel) [61] classification algorithms in conjunction with RFE (combinations 5 1 0 henceforth referred to as LR-RFE and SVM-RFE respectively). For this, for a given inner CV 5 1 1 training split, all the features (genes) were ranked using the absolute values of the weights 5 1 2 assigned to them by an inner classification model, trained using the LR or SVM algorithm, over 5 1 3 this split. Next, for each of the conjunctions, the set of top-k ranked features, with k starting with 5 1 4 11587 (all filtered genes) and being reduced by 10% in each iteration until k=1, was considered. 5 1 5
The discriminative strength of feature sets consisting of the top k features as per this ranking 5 1 6 was assessed by evaluating the performance of the LR or SVM classifier based on them over all 5 1 7 the inner CV training-test splits. The optimal number of features to be selected was determined 5 1 8
as the value of k that produces the best performance. Next, a ranking of features was derived 5 1 9 from the outer CV training split using exactly the same procedure as applied to the inner CV 5 2 0 training split. The optimal number of features determined above was selected from the top of 5 2 1 P a n d e y e t a l . , p . 2 3 this ranking to determine the optimal set of predictive features for this outer CV training split. 5 2 2
Executing this process over all the five outer CV training splits created from the development set 5 2 3 identified five such sets. Finally, the set of features (genes) that was common to all these sets 5 2 4 (i.e. in their intersection/overlap), which is expected to yield a more robust feature set than the 5 2 5 individual outer CV splits, was selected as the predictive gene set for this training set. One such 5 2 6 set was identified for each application of LR-RFE and SVM-RFE to the training set. 5 2 7 then applied to the corresponding holdout set to generate probabilistic asthma predictions for 5 3 2 the samples. An optimal threshold for converting these probabilistic predictions into binary ones 5 3 3 (higher than threshold=asthma, lower than threshold=no asthma) was then computed as the 5 3 4 threshold that yielded the highest classification performance on the holdout set. This 5 3 5 optimization resulted in the proposed classification models. 5 3 6
Statistical analyses of classification performance: After the above components were run 5 3 7 on 100 training-holdout splits of the development set, we obtained 100 proposed classification 5 3 8 models for each of eight feature selection-global classification combinations (two feature 5 3 9 selection algorithms (LR-RFE and SVM-RFE) and four global classification algorithms Logistic, 5 4 0 SVM-Linear, AdaBoost and RF). The next step of our pipeline was to determine the best 5 4 1 performing combination. Instead of making this determination just based on the highest 5 4 2 evaluation score, as is typically done in machine learning studies, we utilized this large 5 4 3 population of models and their optimized holdout evaluation scores to conduct a statistical 5 4 4 comparison to make this determination. Specifically, we applied the Friedman test followed by 5 4 5
the Nemenyi test [18, 64] to this population of modules and their evaluation scores. These tests, 5 4 6 which account for multiple hypothesis testing, assessed the statistical significance of the relative 5 4 7 P a n d e y e t a l . , p . 2 4 difference of performance of the combinations in terms of their relative ranks across the 100 5 4 8 splits.
4 9
Optimization for parsimony: For a phenotype classifier, it is essential to consider 5 5 0 parsimony in model selection (i.e. minimize number of features (i.e. genes)) to enhance its 5 5 1 clinical utility and acceptability. To enforce this for our asthma classifier, an adapted 5 5 2 performance measure, defined as the absolute performance measure (F-measure) divided by 5 5 3 the number of genes in that model, was used for the above statistical comparison, i.e. as input 5 5 4
to the Friedman-Nemenyi tests. In terms of this measure, a model that does not obtain the best 5 5 5 performance measure among all models, but uses much fewer genes than the others, may be 5 5 6
judged to be the best model. The result of the statistical comparison using this adapted measure 5 5 7 was visualized as a Critical Difference plot [18] (Supplementary Figure 4) , and enabled us to 5 5 8 identify the best combination of feature selection and classification method as the left-most entry 5 5 9 in this plot. 5 6 0
Final model development: The final step in our pipeline was to determine the 5 6 1 representative model out of the 100 learned the above best combination by finding which of 5 6 2 these models yielded the highest evaluation measure (F-measure; Box 1 and Supplementary 5 6 3 Figure 5 ). In case of ties among multiple candidates, the gene set that produced the best 5 6 4 average asthma classification F-measure across all four global classification algorithms was 5 6 5 chosen as the gene set constituting the representative model for that combination. This analysis 5 6 6 yielded the representative gene set, global classification algorithm, and the optimized asthma 5 6 7 classification threshold. The asthma classifier was built by training the global classification 5 6 8 algorithm to the expression profiles of the representative gene set, and using the optimized 5 6 9 threshold for classifying samples positive/negative for asthma. 5 7 0 5 7 1
Evaluation of the Asthma Classifier in an RNAseq test set of independent subjects 5 7 2 P a n d e y e t a l . , p .
2 5
The asthma classifier identified by our machine learning pipeline was then tested on the 5 7 3
RNAseq test set (n=40) to assess its performance in independent subjects. F-measure was 5 7 4 used as the primary measure for classification performance, as described in Box 1 and 5 7 5
Supplementary Figure 5 . AUC, PPV and NPV were additionally calculated for context. 5 7 6 5 7 7
Comparison of Performance to Alternative Classification Models 5 7 8
Although our classifier was identified using a rigorous machine learning methodology, 5 7 9 the pipeline explored several other models from all combinations of feature selection and global 5 8 0 classification methods. Thus, we compared the performance of our classifier with all these other 5 8 1 possible classifiers. 5 8 2 Also, our methodology was not the only way to develop gene expression-based 5 8 3 classifiers. Thus, we also compared the classifier's performance with several other valid 5 8 4 methods by applying our machine learning pipeline with the feature (gene) selection step 5 8 5
replaced with the following alternatively determined gene sets: (1) all filtered RNAseq genes, (2) 5 8 6 all differentially expressed genes, and (3) known asthma genes from a recent review of asthma 5 8 7
genetics [33] . To maintain consistency with the machine learning pipeline-derived models, each 5 8 8 of these gene sets was run through the same pipeline (Supplementary Figure 2 with the 5 8 9 feature selection component turned off) to identify the best performing global classification 5 9 0 algorithm and the optimal asthma classification threshold for this predetermined set of features. 5 9 1
The algorithm and threshold were used to train each of these gene sets' representative 5 9 2 classification model over the entire development set, and the resulting models for each of these 5 9 3 gene sets were then evaluated on the RNAseq test set. Finally, as a baseline representative of 5 9 4 alternative sparse classification algorithms, which represent a one-step option for doing feature 5 9 5 selection and classification simultaneously, we also trained an L1-regularized logistic regression 5 9 6 model (L1-Logistic) [34] on the development set and evaluated it on the RNAseq test set. 5 9 7 5 9 8 P a n d e y e t a l . , p .
Comparison of Performance to Permutation-based Random Models 5 9 9
To determine the extent to which the performance of all the above classification models 6 0 0 could have been due to chance, we compared their performance with that of their random 6 0 1 counterpart models (Supplementary Figures 6 and 7) . These counterparts were obtained by 6 0 2 randomly permuting the labels of the samples in the development set and executing each of the 6 0 3 above model training procedures on these randomized data sets in the same way as for the real 6 0 4 development set. These random models were then applied to each of the test sets considered 6 0 5 in our study, and their performances were also evaluated in terms of the same measures. For 6 0 6 each of real models tested in our study, 100 corresponding random models were learned and 6 0 7 evaluated as above, and the performance of the real models was compared with the average 6 0 8 performance of the corresponding random models. 6 0 9 6 1 0
Evaluation of the asthma classifier in external independent asthma cohorts 6 1 1
To assess the generalizability of the asthma classifier to other populations, microarray-6 1 2 profiled data sets of nasal gene expression from two external asthma cohorts--Asthma1 6 1 3 (GSE19187) [35] and Asthma2 (GSE46171) [36] ( Supplementary Table 3 )--were obtained 6 1 4 from NCBI Gene Expression Omnibus (GEO) [65] . For each of these data sets, we obtained 6 1 5 their probe-level normalized versions from GEO, and then obtained gene-level expression 6 1 6 profiles by averaging the normalized expression of all the probes corresponding to the same 6 1 7 gene. The probe-to-gene mappings were obtained from the microarray platform (GPL) files also 6 1 8 available from GEO. The asthma classifier was then applied to these gene-level data sets and 6 1 9 its performance evaluated on these external asthma cohorts. 6 2 0 6 2 1
Evaluation of the asthma classifier in external cohorts with other respiratory conditions 6 2 2
To assess the classifier's ability to distinguish asthma from respiratory conditions that 6 2 3
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We thank Robert Griffin and Ana Stanescu for critically reviewing the paper. 6 6 1 P a n d e y e t a l . , p . 3  6  .  M  c  E  r  l  e  a  n  P  ,  B  e  r  d  n  i  k  o  v  s  S  ,  F  a  v  o  r  e  t  o  S  ,  J  r  .  ,  S  h  e  n  J  ,  B  i  y  a  s  h  e  v  a  A  ,  B  a  r  b  e  a  u  R  ,  E  i  s  l  e  y  C  ,  B  a  r  c  z  a  k  A  ,  W  a  r  d  T  ,  S  c  h  l  e  i  m  e  r  R  P  ,  e  t  a  l  :  A  s  t  h  m  a  t  i  c  s  w  i  t  h  e  x  a  c  e  r  b  a  t  i  o  n  d  u  r  i  n  g  a  c  u  t  e  r  e  s  p  i  r  a  t  o  r  y  i  l  l  n  e  s  s  e  x  h  i  b  i  t  u  n  iu  e  t  r  a  n  s  c  r  i  p  t  i  o  n  a  l  s  i  g  n  a  t  u  r  e  s  w  i  t  h  i  n  t  h  e  n  a  s  a  l  m  u  c  o  s  a  .   G  e  n  o  m  e  M  e  d   2  0  1  4  ,  6  :  1  .  3  7  .  Z  h  a  n  g  W  ,  Y  u  Y  ,  H  e  r  t  w  i  g  F  ,  T  h  i  e  r  r  y  -M  i  e  g  J  ,  Z  h  a  n  g  W  ,  T  h  i  e  r  r  y  -M  i  e  g  D  ,  W  a  n  g  J  ,  F  u  r  l  a  n  e  l  l  o  C  ,  D e v a n a r a y a n V , purple groups of rows, respectively. The 33 genes in this set that have been previously studied in the context of asthma are marked in blue. The classifier's inclusion of genes not previously known to be associated with asthma as well as genes not differentially expressed in asthma (beige group of rows) demonstrates the ability of a machine learning methodology to move beyond traditional analyses of differential expression and current domain knowledge. Nasal steroids 14 (9.3%) 9 (17.0%) 5 (5.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.07
Figure Legends
Smoking 7 (4.7%) 1 (1.9%) 6 (6.2%) 1 (2.5%) 0 (0.0%) 1 (3.7%) 1.0 Supplementary Table 1 : Lists of over-and under-expressed genes and pathways in asthma cases compared to controls (in different tabs of this file). Differentially expressed genes were identified using DESeq2 [23] applied to the development set, and enriched pathways were identified from the Molecular Signature Database [24], both using an upper FDR threshold of 0.05.
Mean (SD) or Number (%) provided
Supplementary Table 2:
List of known asthma-associated genes from a review of asthma genetics [33] that overlap with genes in our RNAseq data sets. Supplementary Table 3 : Characteristics of the external asthma cohorts used in the evaluation of the asthma classifier. Supplementary Table 4 : Characteristics of the external cohorts with non-asthma respiratory conditions and controls used in the evaluation of the asthma classifier. Supplementary Table 5 : Basic functional annotations and references for asthma classifier genes that have been studied in the context of asthma and airway inflammation 
